Enclomiphene Citrate

Enclomiphene citrate is the trans-isomer of the well-known fertility drug clomiphene citrate, and it has attracted substantial research interest as a treatment for secondary male hypogonadism — a condition where the testes are functional but receive insufficient hormonal signaling from the brain. With a molecular weight of 598.09 Da and the molecular formula C32H36ClNO8, the compound belongs to the SERM class and was developed by Repros Therapeutics under the brand name Androxal.

Researchers began separating the two geometric isomers of clomiphene — the cis-form (zuclomiphene) and the trans-form (enclomiphene) — because the two have meaningfully different pharmacological profiles. The cis-isomer has a longer half-life and is thought to contribute to some of clomiphene's unwanted estrogenic side effects. Enclomiphene, by contrast, behaves as a clean estrogen receptor antagonist in the hypothalamic-pituitary axis, making it a more targeted approach to stimulating the gonadal axis.

What makes enclomiphene particularly interesting to researchers is its ability to raise testosterone levels while simultaneously preserving — or even improving — sperm production. This stands in direct contrast to exogenous testosterone therapy, which suppresses the hypothalamic-pituitary-gonadal (HPG) axis and routinely causes oligospermia or azoospermia, making it unsuitable for men who wish to retain fertility. A 2014 phase II randomized clinical trial published in Fertility and Sterility found that enclomiphene citrate raised testosterone to eugonadal levels while preventing the decline in sperm counts observed with topical testosterone gel.

The compound has been evaluated in multiple phase II and phase III clinical trials, with particular focus on obese men with secondary hypogonadism — a population in which low testosterone is common and exogenous hormone therapy carries specific metabolic concerns. A 2016 study published in BJU International found that oral enclomiphene citrate raised testosterone and preserved sperm counts in obese hypogonadal men, outcomes not achievable with topical testosterone at equivalent hormonal effect.

Despite reaching phase III trials, enclomiphene citrate did not receive FDA approval, primarily due to regulatory questions around the study design and the adequacy of long-term safety data submitted. Research continues, and the compound is actively studied in comparative analyses against both clomiphene citrate and exogenous testosterone, with its fertility-preserving profile remaining the central focus of ongoing investigation.

Enclomiphene citrate exerts its primary pharmacological effect by blocking estrogen receptors (ERα) in the hypothalamus and anterior pituitary gland. Under normal physiological conditions, circulating estradiol — a product of testosterone aromatization — binds to these receptors and exerts negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis, suppressing the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus. This in turn limits pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

By occupying ERα at the hypothalamus and pituitary without activating downstream estrogenic signaling, enclomiphene acts as a competitive antagonist at these sites. The result is a reduction in the estrogen-mediated inhibitory signal, which disinhibits GnRH pulsatility. Increased GnRH pulse frequency and amplitude then drive the pituitary to secrete greater quantities of LH and FSH.

Elevated LH acts on Leydig cells within the testes, stimulating the conversion of cholesterol to testosterone through the steroidogenic pathway involving steroidogenic acute regulatory protein (StAR) and the CYP11A1 and CYP17A1 enzymes. The resulting increase in intratesticular and serum testosterone is endogenous — produced by the patient's own Leydig cells — rather than exogenously supplied.

Elevated FSH simultaneously acts on Sertoli cells, which support spermatogenesis. This dual gonadotropin stimulation explains why enclomiphene can raise serum testosterone while also maintaining or improving sperm parameters, an outcome mechanistically impossible with exogenous testosterone, which suppresses LH and FSH secretion via a different negative feedback loop.

Enclomiphene is chemically distinguishable from the cis-isomer zuclomiphene by its trans-geometric configuration at the central ethylene bond. This structural difference produces a shorter plasma half-life for enclomiphene and reduces its residual estrogenic agonist activity, which the cis-isomer possesses to a greater degree. A 2013 pharmacokinetics study published in BJU International documented that enclomiphene reaches peak plasma concentration within approximately four hours of oral dosing and clears more rapidly than zuclomiphene, minimizing accumulation and the estrogenic effects associated with the cis-form.

The clinical research on enclomiphene citrate spans multiple randomized controlled trials, systematic reviews, and retrospective studies, with the majority of evidence accumulated between 2013 and 2025. The compound has been studied almost exclusively in men, and the existing evidence base is richer than that for many investigational SERMs.

A 2013 phase II trial published in the Journal of Sexual Medicine compared oral enclomiphene citrate to testosterone gel in men with low testosterone. The trial found that enclomiphene raised serum testosterone into the normal range while maintaining sperm counts, whereas testosterone gel raised testosterone but caused significant reductions in sperm production. This study established the foundational fertility-preserving rationale for enclomiphene research.

A subsequent 2014 phase II randomized clinical trial published in Fertility and Sterility specifically examined the dose-response relationship of enclomiphene citrate (12.5 mg and 25 mg daily) compared to topical testosterone in men with secondary hypogonadism. The study reported that both enclomiphene doses raised morning testosterone to greater than 300 ng/dL, with the 25 mg dose achieving mean levels comparable to testosterone gel, while oligospermia was not observed in the enclomiphene groups.

A 2016 study in BJU International specifically focused on obese hypogonadal men, a population with particular clinical need. Researchers found that oral enclomiphene raised testosterone and preserved sperm counts, while topical testosterone raised testosterone but significantly reduced sperm counts and testicular volume. A companion report published the same year in Nature Reviews Urology highlighted these findings as clinically relevant for the growing population of men with obesity-related hypogonadism.

The 2013 pharmacodynamics and pharmacokinetics study in BJU International characterized the dose-exposure relationship, finding peak plasma concentrations at approximately four hours post-dose and demonstrating that enclomiphene, unlike zuclomiphene, does not accumulate substantially with repeat dosing.

A 2023 retrospective study published in Cureus compared clinical outcomes between clomiphene citrate and enclomiphene citrate in men treated for infertility. The study found enclomiphene produced more selective gonadotropin stimulation with less residual estrogenic activity, consistent with its isomer profile.

The most recent high-level evidence comes from a 2025 systematic review and meta-analysis published in Archives of Endocrinology and Metabolism, which pooled data from randomized controlled trials of clomiphene and enclomiphene in male hypogonadism. The analysis found that both compounds raised LH, FSH, and testosterone, with enclomiphene showing a cleaner hormonal profile. A related 2023 systematic review and meta-analysis published in Andrology examined selective estrogen receptor modulation broadly in obese hypogonadal men, supporting the efficacy signal for enclomiphene in this subgroup.

Human data is available from multiple phases of trial development, though no study has followed participants for more than 12 consecutive months. Animal data are not the primary evidence base for this compound given its advanced clinical development stage.

Published phase II and phase III clinical trials have examined oral enclomiphene citrate at doses of 12.5 mg and 25 mg administered once daily in men with secondary hypogonadism. A 2014 Fertility and Sterility trial used these two doses over a 12- to 26-week treatment period. A 2013 BJU International pharmacokinetics study documented dose-exposure relationships at these same doses. Both dose levels raised serum testosterone into the normal range in the studied populations, with the 25 mg dose producing numerically higher testosterone levels. Doses above 25 mg daily have not been reported in the published peer-reviewed clinical literature.

The safety profile of enclomiphene citrate has been characterized primarily through phase II and phase III clinical trials in men with secondary hypogonadism, spanning treatment durations of up to 26 weeks. Within the studied populations, the compound has generally been well tolerated at doses of 12.5 mg and 25 mg per day.

The most commonly reported adverse effects in clinical trials include visual disturbances, hot flashes, and mood changes — side effects shared with other SERMs and attributed to estrogen receptor blockade at tissue sites beyond the hypothalamus and pituitary. These effects are generally mild and reversible upon discontinuation in the available trial data.

Because enclomiphene acts as an estrogen receptor antagonist, theoretical concerns include effects on bone mineral density and lipid metabolism over extended periods. Estrogen plays an important role in maintaining bone density and cardiovascular lipid profiles in men as well as women, and prolonged antagonism at peripheral receptors could in principle affect these parameters. However, the available clinical trials do not report significant changes in bone density or lipid profiles at the studied durations, and the relatively short follow-up periods mean long-term effects remain uncharacterized.

Enclomiphene's cleaner isomer profile compared to racemic clomiphene citrate means lower theoretical estrogenic agonist activity from residual zuclomiphene, which is the basis for its proposed tolerability advantage. A 2016 Expert Opinion on Pharmacotherapy review noted this distinction as pharmacologically relevant, though head-to-head safety comparisons between the two compounds in adequately powered trials are limited.

No completed trial has followed patients beyond 12 months of continuous use. The long-term effects on the HPG axis, testicular function, and estrogen-sensitive tissues are therefore unknown. Men with pre-existing prostate conditions, liver disease, or thromboembolic risk factors were generally excluded from the published trials, so safety in these subgroups is not established. The compound is not FDA-approved, meaning it is not available outside clinical research or off-label prescribing contexts, and its use carries the inherent risks associated with any unapproved pharmacological agent.

Enclomiphene citrate reached phase III clinical trials under the Androxal brand name but did not receive FDA approval, with regulatory review citing study design and long-term data concerns. It is not approved in the United States or, to the extent of available public record, in any major regulatory jurisdiction as of 2025.

Active research continues in the peer-reviewed literature. A 2025 systematic review and meta-analysis published in Archives of Endocrinology and Metabolism represents the most recent pooled analysis of randomized controlled trial data, and a 2023 Andrology meta-analysis examined the compound's role in obese men with androgen deficiency. Comparative studies against clomiphene citrate remain an active area, with ongoing interest in clarifying whether the isolated trans-isomer offers meaningful clinical advantages over the racemic mixture.

Key research gaps include the absence of trials longer than 12 months, limited data in non-obese hypogonadal populations, and no controlled trials examining effects on bone density or cardiovascular biomarkers as primary endpoints. The fertility-preserving profile of enclomiphene continues to attract interest from reproductive endocrinology researchers.